Medicure submitted a supplemental new drug application with the FDA on Sept. 10 to expand the labeling for tirofiban hydrochloride (Aggrastat) to include patients with ST segment elevation myocardial infarction (STEMI). The company said in a news release that it expects the FDA to make its approval decision by July 2016.

Patients with an acute anterior ST-segment elevation MI (STEMI) who were injected with cyclosporine immediately before undergoing PCI did not have better clinical outcomes compared with a group receiving placebo, according to a randomized, double-blind trial.

More than six percent of patient who underwent successful PCI with drug-eluting stents had post-discharge bleeding within two years, according to a prospective study. A multivariable analysis found post-discharge bleeding was the strongest predictor of two-year mortality.

Building a Protected PCI Program: The Heart Team Approach

After six months of follow-up, all three patients in a recent trial who underwent transcatheter mitral valve replacement (TMVR) to treat mitral valve disease remained alive and were not readmitted to hospitals for heart failure. The patients were treated with the Fortis mitral transcatheter heart valve, which is not FDA-approved.

A prediction model developed by researchers in Boston found that anticoagulation treatment, frequency of emergency department visits before the procedure and anxiety were associated with early hospital readmission after patients underwent PCI.

Patients who underwent early surgery for mitral regurgitation were less likely to have postoperative mortality and heart failure compared with those who waited for rescue surgery, according to a Mayo Clinic analysis.

For patients with type 2 diabetes and stable ischemic heart disease, measuring their cardiac troponin T concentration may help predict their risk of death from cardiovascular causes, nonfatal MI or nonfatal stroke, according to an analysis of a randomized study.